Gastrin-releasing peptide precursor 164 is not necessarily lung cancer, greater than 46ng/L suggests that the value is elevated, there is a possibility of lung cancer, but also need to be considered in conjunction with other tests.
Gastrin-releasing peptide precursor is a specific tumor marker for small cell lung cancer, with higher sensitivity and specificity, and better specificity than neuron-specific enolase.
If serum gastrin-releasing peptide precursor is greater than 150 ng/L and neuron-specific enolase is greater than 15 ng/ml, the patient has a high reliability for the diagnosis of small cell lung cancer. Lung cancer cannot be diagnosed based on gastrin-releasing peptide precursor 164ng/L alone, and it should also be combined with the results of chest CT and puncture pathology to make a comprehensive judgment, of which pathologic diagnosis is the gold standard.
If patients find elevated serum gastrin-releasing peptide precursor, they should consult a doctor in time to clarify the cause of the disease and treat it as early as possible.